Apellis announces FDA approval of EMPAVELI Injector

Apellis Pharmaceuticals announced that the U.S. Food and Drug Administration has approved the EMPAVELI Injector. The EMPAVELI Injector is a compact, single-use, on-body device designed to enhance self-administration of EMPAVELI, which is approved for adults with paroxysmal nocturnal hemoglobinuria/ The EMPAVELI Injector is the first high-volume, subcutaneous on-body delivery system which features several advances to streamline self-administration. The compact device offers patients greater mobility when administering EMPAVELI. A push button starts the injection, and the hidden needle automatically retracts upon dose completion. The EMPAVELI Injector is developed in collaboration with Enable Injections, based on the enFuse Syringe Transfer System.